SCHEMBL29387941

SCHEMBL29387941

Cc1cc(NC(=O)c2ccc(C(F)(F)C(=O)N3CCC(O)CC3)n2C)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ DRD4 P21917 2/20 0.37
▸ KCNJ6 P48051 2/20 0.36
▸ KCNJ5 P48544 2/20 0.36
▸ KCNJ3 P48549 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ TMEM97 Q5BJF2 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ EPHX2 P34913 3/20 0.35
▸ HTR1F P30939 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21062119 1.00 CYP3A4 (0.38) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL29390977 0.84 DRD4 (0.36) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL21062175 0.84 DRD4 (0.36) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL21146069 0.84 ABL1 (0.39) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL29389917 0.84 ABL1 (0.39) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL29390420 0.82 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL21146066 0.82 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL29390725 0.81 HTR2B (0.42) HTR2BPOLBMEN1KMT2AHTR1F
SCHEMBL21145868 0.81 HTR2B (0.42) HTR2BPOLBMEN1KMT2AHTR1F
SCHEMBL21146538 0.80 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247965-B2 Hepatitis B capsid assembly modulators VenatoRx Pharmaceuticals, Inc. (US) 2022-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247965-B2 Hepatitis B capsid assembly modulators HAVCR2, COPB1, HDLBP CYP3A4 2465/4885CYP2D6 4268/4885CYP2C9 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback